Research programme: transmucosal therapeutics - ULURU
Latest Information Update: 25 Sep 2009
At a glance
- Originator ULURU
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Migraine; Pain
Most Recent Events
- 25 Sep 2009 Discontinued - Preclinical for Migraine in USA (Transmucosal)
- 25 Sep 2009 Discontinued - Preclinical for Pain in USA (Transmucosal)